Updated:
Humedix
Kim Jin-hwan established Humedix in 1999 as a hyaluronic acid specialist, supplying the raw material that would fuel South Korea's rise as the world's...
Humedix
Kim Jin-hwan established Humedix in 1999 as a hyaluronic acid specialist, supplying the raw material that would fuel South Korea's rise as the world's aesthetic-procedure capital. The company began by perfecting bacterial fermentation to produce ultra-pure sodium hyaluronate at pharmaceutical grade, initially serving ophthalmic surgery markets before entering dermatology. That dual-track foundation — surgical viscoelastics and injectable fillers — remains Humedix's intellectual anchor two decades later. Humedix deploys capital across three linked verticals: bulk Active Pharmaceutical Ingredient sales to global pharma buyers, branded filler products sold through its own medical-device division, and joint-venture manufacturing for multinationals seeking Korea-based production. The company's filler portfolio, led by the Elravie and Hyafilia lines, competes directly with Allergan's Juvederm and Galderma's Restylane in Asian markets. Humedix also produces ophthalmic viscoelastics sold under the Hyalein brand and operates a contract manufacturing business that has produced HA-based products for LG Household & Health Care. Its geographic footprint concentrates on South Korea, China, and Southeast Asia, with growing distribution in Europe and Latin America. As of its most recent disclosures, Humedix operates manufacturing facilities in Seongnam and Chungju, South Korea, with research teams focused on next-generation cross-linking technologies and sustained-release drug delivery platforms using HA as a carrier. The company completed a major capacity expansion at its Chungju plant in 2023, adding fermentation lines intended to increase API output for export markets. November 2023: Humedix received updated CE marking certification under EU Medical Device Regulation for its Hyafilia filler range, reopening European distribution channels after the regulatory transition period. Humedix's structural differentiator is its status as one of fewer than ten firms worldwide with end-to-end HA manufacturing — from strain engineering through cGMP API production to finished sterile device — allowing operating margins that third-party formulators cannot replicate. The company has signaled interest in moving beyond fillers into HA-based drug delivery, positioning its polymer chemistry expertise against the injectable drug-device combination products that large pharma pipelines increasingly demand.
General information
Firm type
Asset Manager
Year founded
1999
AUM
Undisclosed
Location
Region
Asia
Country
South Korea
City
Seongnam
Corporate office
Seongnam, Gyeonggi-do, South Korea
Sector focus
Frequently asked questions
Who runs investment decisions at Humedix?
Humedix is an operating pharmaceutical and medical-device company, not an investment firm. Capital allocation decisions are made by its executive management and board of directors, led by founder Kim Jin-hwan, who remains the company's largest shareholder. The company does not maintain a separate investment committee structure of the type allocators evaluate at family offices or fund managers.
What is Humedix's core competitive advantage in the HA filler market?
Humedix is one of fewer than ten firms globally that control the full hyaluronic acid value chain — from bacterial strain engineering and fermentation-based API production through sterile filling and finished-device packaging. This vertical integration, anchored at facilities in Seongnam and Chungju, provides cost advantages over competitors that purchase bulk HA from third-party suppliers. The company's fermentation technology produces high-purity, low-endotoxin sodium hyaluronate suitable for both ophthalmic surgery and injectable aesthetics.
Which filler brands does Humedix manufacture, and who do they compete against?
Humedix's primary filler brands are Elravie and Hyafilia, positioned primarily in Asian and Latin American markets. These products compete directly against Allergan's Juvederm (AbbVie) and Galderma's Restylane, as well as against domestic Korean competitors including LG Chem's Yvoire and Medytox's Neuramis lines. Humedix also acts as a contract manufacturer for third-party HA products, including historical production for LG Household & Health Care.
What regulatory certifications does Humedix hold for international distribution?
Humedix holds Korean MFDS (Ministry of Food and Drug Safety) approvals for all domestic products. In international markets, the company received updated CE marking certification under the European Union Medical Device Regulation (EU MDR) in November 2023 for its Hyafilia filler range, and maintains approvals in China through the NMPA, as well as registrations in multiple Southeast Asian, Middle Eastern, and Latin American markets.
Does Humedix operate as a family office or manage outside capital?
No. Humedix is a publicly traded operating company listed on the KOSDAQ exchange in South Korea (ticker: 200670). It is a pharmaceutical and medical-device manufacturer, not an investment vehicle. Founder Kim Jin-hwan and his family hold a significant ownership stake, but the company raises capital through public equity markets and retained earnings, not as a family office deploying personal wealth.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: